top of page

News Highlights

Check this page for recent news from Appili Therapeutics.

Members of the media can contact us here, or for general inquiries, contact us here.

March 20, 2023
Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings
February 14, 2023
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023
February 8, 2023
Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA
January 17, 2023
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
January 13, 2023
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
bottom of page